secwatch / observer
8-K filed June 30, 2022, 7:59 PM ET ticker ALLR CIK 0001860657
leadership confidence high sentiment negative materiality 0.80

Allarity Therapeutics CEO Steve Carchedi and CFO Jens Knudsen resign; James Cullem interim CEO, Joan Brown interim CFO

Allarity Therapeutics, Inc.

item 5.02item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

James Cullem

interim Chief Executive Officer
ALLR · Allarity Therapeutics, Inc.
Effective
2022-06-29
Filed
June 30, 2022, 7:59 PM ET
the Board of Directors of the Company (the “Board”) appointed James Cullem, the Company’s current Chief Business Officer, as the interim Chief Executive Officer of the Company effective as of June 29, 2022.
Departed (interim)

Steve Carchedi

Chief Executive Officer
ALLR · Allarity Therapeutics, Inc.
Effective
2022-06-29
Successor
James Cullem
Filed
June 30, 2022, 7:59 PM ET
Effective as of June 29, 2022, Steve Carchedi resigned from all positions in Allarity Therapeutics, Inc. (the “Company”), and all positions of its subsidiaries, including his role of Chief Executive Officer and as a director of the Company.
Departed (interim)

Jens Knudsen

Chief Financial Officer
ALLR · Allarity Therapeutics, Inc.
Effective
2022-06-27
Successor
Joan Brown
Filed
June 30, 2022, 7:59 PM ET
Effective as of June 27, 2022, Jens Knudsen resigned from all positions in the Company, and all positions of its subsidiaries, including his role of Chief Financial Officer of the Company.
Appointed (interim)

Joan Brown

interim Chief Financial Officer
ALLR · Allarity Therapeutics, Inc.
Effective
2022-06-29
Filed
June 30, 2022, 7:59 PM ET
the Board appointed Joan Brown, the Company’s current Director of Financial Reporting, as the interim Chief Financial Officer of the Company effective as of June 29, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James Cullem was appointed as interim Chief Executive Officer at Allarity Therapeutics, Inc..

Action
appointed
Role
interim Chief Executive Officer
Exact text from the filing
the Board of Directors of the Company (the “Board”) appointed James Cullem, the Company’s current Chief Business Officer, as the interim Chief Executive Officer of the Company effective as of June 29, 2022.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Steve Carchedi resigned as Chief Executive Officer at Allarity Therapeutics, Inc..

Action
resigned
Role
Chief Executive Officer
Exact text from the filing
Effective as of June 29, 2022, Steve Carchedi resigned from all positions in Allarity Therapeutics, Inc. (the “Company”), and all positions of its subsidiaries, including his role of Chief Executive Officer and as a director of the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Jens Knudsen resigned as Chief Financial Officer at Allarity Therapeutics, Inc..

Action
resigned
Role
Chief Financial Officer
Exact text from the filing
Effective as of June 27, 2022, Jens Knudsen resigned from all positions in the Company, and all positions of its subsidiaries, including his role of Chief Financial Officer of the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Joan Brown was appointed as interim Chief Financial Officer at Allarity Therapeutics, Inc..

Action
appointed
Role
interim Chief Financial Officer
Exact text from the filing
the Board appointed Joan Brown, the Company’s current Director of Financial Reporting, as the interim Chief Financial Officer of the Company effective as of June 29, 2022.
View on SEC.gov

Allarity Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001213900-22-036020
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.